M. Mosca (Pisa), R. Perricone (Roma) - Sir

Diagnosi precoce nel LES 109
in particolare la glomerulonefrite e le manifestazioni
neuropsichiatriche, attraverso il dosaggio di
semplici biomarkers, potrebbe essere molto utile
nei pazienti affetti da LES e potrebbe consentire un
intervento terapeutico tempestivo migliorando la
prognosi a lungo termine e la qualità di vita.
BIBLIOGRAFIA
1. Doria A, Iaccarino L, Ghirardello A, et al. Long-term
prognosis and causes of death in systemic lupus erythematosus.
Am J Med 2006; 119: 1497-9.
2. Bano S, Bombardieri S, Doria A, et al. Lupus erythematosus
and the skin. Clin Exp Rheumatol 2006; 24:
S26-S35.
3. Doria A, Vesco P, Zulian F, Gambari PF. The 1982
ARA/ACR criteria for classification of systemic lupus
erythematosus in pediatric age. Clin Exp Rheumatol
1994; 12: 689-90.
4. Ghirardello A, Bendo R, Rampudda ME, Bassi N,
Zampieri S, Doria A. Commercial blot assays in the diagnosis
of systemic rheumatic diseases. Autoimmun
Rev. 2009 Feb 11. [Epub ahead of print].
5. Villata D, Romelli PB, Savina C, et al. Anti-dsDNA antibody
avidity determination by simple reliable ELISA
method for SLE diagnosis and monitoring. Lupus 2003;
12: 31-36.
6. Zampieri S, Ghirardello A, Doria A, et al. The use of
Tween 20 in immunoblotting assays for the detection
of autoantibodies in connective tissue diseases. J Immunol
Methods 2000; 239: 1-11.
7. Ghirardello A, Doria A, Vesco P, et al. Blotting patterns
of IgG anti-(U1)RNP antibodies in mixed connective
tissue disease. Rheumatol Int 1996; 16: 145-50.
8. Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin
antibodies predict thrombosis in patients with
systemic lupus erythematosus: a 15-year longitudinal
study. J Thromb Haemost 2007; 5: 1158-64.
9. Ghirardello A, Doria A, Ruffatti A, et al. Antiphospholipid
antibodies (aPL) in systemic lupus erythematosus
(SLE). Are they specific tools for the diagnosis
of aPL syndrome in SLE? Ann Rheum Dis 1994; 53:
140-2.
10. Doria A, Mosca M, Gambari PF, Bombardieri S. Defining
unclassifiable connective tissue diseases: incomplete,
undifferentiated or both? J Rheumatol 2005; 32:
213-5.
11. Doria A, Ghirardello A, de Zambiasi P, Ruffatti A,
Gambari PF. Japanese diagnostic criteria for mixed
connective tissue disease in Caucasian patients. J
Rheumatol 1992; 19: 259-64.
12. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. Update
on idiopathic inflammatory myopathies. Autoimmunity.
2006; 39: 161-70.
13. Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections,
rheumatism and autoimmunity: the conflicting relationship
between humans and their environment. Autoimmun
Rev 2008; 8:1-4.
14. Doria A, Zampieri S, Sarzi-Puttini P. Exploring the
complex relationships between infections and autoimmunity.
Autoimmun Rev 2008; 8: 89-91.
15. Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A. Environment
and systemic lupus erythematosus: an
overview. Autoimmunity 2005: 38: 465-72.
16. Doria A, Canova M, Tonon M, et al. Infections as triggers
and complications of systemic lupus erythematosus.
Autoimmun Rev 2008; 8: 24-8.
17. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical
atherosclerosis in a prospective cohort of patients
with systemic lupus erythematosus. Ann Rheum
Dis 2003, 62: 1071-77.
18. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis
in autoimmune rheumatic diseases. Circulation
2005; 112: 3337-47.
19. Doria A, Shoenfeld Y, Pauletto P. Premature coronary
disease in systemic lupus. N Eng J Med 2004; 350(15):
1571-5.
20. Doria A, Sherer Y, Meroni PL, Shoenfeld Y. Inflammation
and accelerated atherosclerosis – basic mechanisms.
Rheum Dis Clin N Am 2005; 31: 329-54.
21. Rinaldi S, Doria A, Salaffi F, et al. Health-related quality
of life in Italian patients with systemic lupus erythematosus.
I. Relationship between physical and mental
dimension and impact of age. Rheumatology 2004;
43: 1574-9.
22. Doria A, Rinaldi S, Ermani M, et al. Health-related
quality of life in Italian patients with systemic lupus
erythematosus. II. Role of clinical, immunological, and
psychological determinants. Rheumatology 2004; 43:
1580-6.
23. Rinaldi S, Ghisi M, Iaccarino L, et al. Influence of coping
skills on health-related quality of life in SLE patients.
Arthritis Rheum 2006; 55: 427-33.
24. Doria A, Briani C. Primary prevention of systemic lupus
erythematosus. Nat Clin Pract Rheumatol 2008; 4:
576-7.
25. Doria A, Briani C. Lupus: improving long-term prognosis.
Lupus 2008; 17: 166-70.
26. Doria A, Arienti S, Rampudda M, Canova M, Tonon
M, Sarzi-Puttini P. Preventive strategies in systemic lupus
erythematosus. Autoimmun Rev 2008; 7: 192-7.
27. Ghirardello A, Doria A, Villalta D, Zampieri S, Tozzoli
R, Gambari PF. Gli anticorpi antinucleosomi: nuovo
marker sierologico di lupus eritematoso sistemico.
Reumatismo 2000; 52: 242-8.
28. Ghirardello A, Doria A, Zampieri S, et al. Antinucleosome
antibodies in SLE: a two-year follow-up study of
101 patients. J Autoimmunity 2004; 22: 235-40.
29. Ghirardello A, Doria A, Zampieri S, Gambari PF, Todesco
S. Autoantibodies to ribosomal P proteins in systemic
lupus erythematosus. Isr Med Assoc J 2001; 3:
854-7.
30. Zampieri S, Degen W, Ghirardello A, Doria A, van
Venrooij WJ. Dephosphorylation of autoantigenic ribosomal
P proteins during Fas-L induced apoptosis; a
possible trigger for the development of the autoimmune
response in SLE patients. Ann Rheum Dis 2001;
60: 72-6.